NASDAQ · QNRX
Healthcare · Biotechnology
$5.57
Up+$0.58 (+11.62%)
Updated Aug 22, 2026, 5:14 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
QNRX closed at $5.57 after 21 trading sessions, up 30.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $5.29 | $5.88 | $5.02 | $5.57 | 72.11K |
| Aug 20, 2026 | $4.85 | $5.225 | $4.639 | $4.99 | 8.12K |
| Aug 19, 2026 | $4.90 | $4.955 | $4.60 | $4.72 | 21.31K |
| Aug 18, 2026 | $4.97 | $5.00 | $4.749 | $4.97 | 9.71K |
| Aug 17, 2026 | $4.76 | $5.20 | $4.76 | $5.19 | 17.08K |
| Aug 14, 2026 | $5.00 | $5.30 | $4.55 | $5.09 | 64.75K |
| Aug 13, 2026 | $5.79 | $6.38 | $5.65 | $6.05 | 37.38K |
| Aug 12, 2026 | $5.20 | $5.91 | $5.20 | $5.89 | 38.75K |
| Aug 11, 2026 | $5.30 | $5.35 | $5.05 | $5.35 | 10.32K |
| Aug 10, 2026 | $4.84 | $5.36 | $4.655 | $5.36 | 22.86K |
| Aug 7, 2026 | $4.79 | $4.90 | $4.695 | $4.79 | 17.37K |
| Aug 6, 2026 | $4.40 | $4.70 | $4.325 | $4.57 | 30.26K |
| Aug 5, 2026 | $4.2719 | $4.37 | $4.25 | $4.37 | 6.38K |
| Aug 4, 2026 | $4.3794 | $4.50 | $4.30 | $4.35 | 9.11K |
| Aug 3, 2026 | $4.37 | $4.49 | $4.25 | $4.45 | 17.95K |
| Jul 31, 2026 | $4.1708 | $4.47 | $4.1708 | $4.45 | 7.31K |
| Jul 30, 2026 | $4.21 | $4.40 | $3.99 | $4.40 | 40.08K |
| Jul 29, 2026 | $4.25 | $4.37 | $4.22 | $4.275 | 6.22K |
| Jul 28, 2026 | $4.2234 | $4.3699 | $4.20 | $4.20 | 8.52K |
| Jul 27, 2026 | $4.20 | $4.3192 | $4.18 | $4.29 | 8.34K |
| Jul 24, 2026 | $4.27 | $4.29 | $4.20 | $4.28 | 6.33K |
The latest Smart Investors Daily articles mentioning QNRX.
QNRX research
Company profile and research snapshot.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Mar 15, 2024 | Maxim Group | Buy | — |
| Sep 7, 2022 | Alliance Global Partners | Buy | — |
| May 6, 2022 | Ladenburg Thalmann | Buy | — |
| Jan 7, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 11, 2026
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan
defenseworld.net · Dec 4, 2025
Quoin Pharmaceuticals (NASDAQ: QNRX - Get Free Report) and Nutriband (NASDAQ: NTRB - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends. Insider and Institutional Ownership 8.6% of Quoin Pharmaceuticals
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QNRX.
